HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Dipyridamol
DIPYRIDAMOL · Dipiridamol · dypyridamole · Anginal · persantin · Persantine · Dipyrdamole · Dipyridamole (200 mg)
Identifikatoren & physikalische Daten
| CAS No. | 58-32-2 |
|---|---|
| Summenformel | C24H40N8O4 |
| Durchschnittliche Molmasse | 504,6 g/mol |
| Monoisotopische Masse | 504,31725176 g/mol |
| SMILES | OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1 |
| InChIKey | IZEKFCXSFNUWAM-UHFFFAOYSA-N |
| PubChem CID | 3108 |
| ChEMBL | CHEMBL932 |
| ChEBI | CHEBI:4653 |
| EC No. | 200-374-7 |
| DTXSID | DTXSID6040668 |
| Lokaler Name | Dipyridamol |
Chemische & physikalische Eigenschaften
| XLogP | 0,7 |
|---|---|
| Polarare Oberfläche (TPSA) | 145 |
| H-Brücken-Donoren | 4 |
| H-Brücken-Akzeptoren | 12 |
| Frei drehbare Bindungen | 12 |
| Schwere Atome | 36 |
| Formalladung | 0 |
| Komplexität | 561 |
| Arzneimittel | Pharmaceuticals -> Listed in ZINC15Pharmaceuticals -> Used in Switzerland |
| LogP (Verteilungskoeffizient) | 1.5 |
| Löslichkeit | Slightly9.22e-01 g/L10.7 [ug/mL] (The mean of the results at pH 7.4)DMSO: solubleSoluble in chloroform, methanol, dilute acids, ethanol. Slightly soluble in water. |
| Human Drugs | BreastfeedingLactationMilk, HumanPhosphodiesterase InhibitorsVasodilator AgentsPlatelet Aggregation InhibitorsFDA approved drugs -> Active ingredientPharmaceuticals |
| Schmelzpunkt | 163 °C165-166 °C (lit.) |
| Physical Description | Solid |
| Collision Cross Section | 223.9 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]227.5 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]222.83 Ų [M+H]+ [CCS Type: TW |
| Siedepunkt | 593.96°C (rough estimate) |
| Dichte | 1.2046 (rough estimate) |
| Brechungsindex | 1.6910 (estimate) |
| Lagerbedingungen | room temp |
| Aggregatzustand | powder |
| pKa (Säurekonstante) | pKa 6.4 (Uncertain) |
| Farbe | yellow |
| Merck | 14,3346 |
| Stabilität | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| InChI | InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2 |
| InChIKey | IZEKFCXSFNUWAM-UHFFFAOYSA-N |
| SMILES | C1(N(CCO)CCO)=NC(N2CCCCC2)=C2N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=N1 |
| NIST chemische Informationen | Pyrimidine, 2,6-bis(diethanolamino)-4,8-dipiperidino-pyrimido-(5,4-d)-(58-32-2) |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH315 (98.7%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 75 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Weitere Sicherheitsinformationen | IMAP assessments - Ethanol, 2,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-: Environment tier I assessment |
| Hazard Classes and Categories | Skin Irrit. 2 (98.7%) |
| Hepatotoxicity | Dipyridamole has been associated with a low rate of serum enzyme elevations during therapy, but in large clinical trials the frequency of liver enzyme abnormalities was similar with dipyridamole therapy as with placebo. Cases of clinically apparent acute liver injury from dipyridamole have not been published although hepatitis is listed as a potential side effect in the product label. The clinical features of the liver injury linked to dipyridamole have not been described. |
| Unerwünschte Wirkungen | The most frequently reported adverse effects include: |
| Toxizitätsübersicht | Signs and Symptoms of Overdose |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)DipyridamoleAmbiguous-DILI-concern3Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| Wassergefährdungsklasse (WGK) | 2 |
| Zollcode | 29335990 |
| RTECS-Nr. | KK7450000 |
| R-Sätze (R) | 36/37/38 |
| Toxizität | LD50 in rats: 8.4 g/kg orally208 mg/kg i.v. (Takenaka) |
| Gefahrensymbole | Xi |
| Sicherheitshinweise (S) | 26-36 |
| Lagerklasse | 11 - Combustible Solids |
Anwendungen & Verwendung
Verwenden
Dipyridamole prevents platelets sticking to the replacement heart valve and causing a blood clot on the valve. It is used to dilate blood vessels in people with peripheral arterial disease and coronary artery disease. This compound has been shown to suppress high glucose-induced osteopontin mRNA expression and protein secretion, as well as inhibit cAMP and cGMP hydrolysis. Research indicates that Dipyridamole is a non-specific nucleoside transport inhibitor with the ability to increase the effects of adenosine in sinoatrial and atrioventricular nodes. Dipyridamole is an inhibitor of ENT1 and ENT2.